Prostate Cancer P D:低PSA分泌型者的临床和基因组特征研究

2020-04-26 AlexYang MedSci原创

转移性疾病负担与血清PSA不成比例已经成为前列腺癌恶性表型的一个标记,但是仍未明确定义为一个独特的亚群。最近,有研究人员前瞻性的鉴定了低PSA分泌型的分子特性和临床结果。

转移性疾病负担与血清PSA不成比例已经成为前列腺癌恶性表型的一个标记,但是仍未明确定义为一个独特的亚群。最近,有研究人员前瞻性的鉴定了低PSA分泌型的分子特性和临床结果。

研究共包括了183名患者,包括了15名(18%)使用最优PSA截断值5ng/mL鉴定为低PSA分泌型的患者。与正常PSA分泌相比,来自低PSA分泌型的活检样本具有更高的t-SCNC和RB1损失以及更低的AR转录特征评分。RB1和/或TP53基因组缺失在低PSA分泌型中更加常见(80% vs. 41%)。低PSA分泌型具有更短的总生存(OS)(中值OS=26.7 vs. 46.0个月, 风险比=2.465 (95% CI: 0.982-6.183)。AR靶向治疗活检后无进展生存(PFS)要比化疗更短(中值PFS6.2 vs. 4.1个月)。

最后,研究人员指出,与转移性肿瘤负担相关的低PSA分泌也许是低分化mCRPC的一种可用的临床选择工具,且具有与t-SCNC一致的分子特征,但仍需前瞻性鉴定。

原始出处:

Rahul Aggarwal, Gustavo Rubio Romero, Verena Friedl et al. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer P D. 14 April 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1682605, encodeId=7d45168260521, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jul 10 16:14:27 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791614, encodeId=cd0f1e91614f5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 03 10:14:27 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382349, encodeId=3b9138234945, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Apr 30 06:11:44 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271084, encodeId=d1df12e1084c6, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364592, encodeId=29d91364592f8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602266, encodeId=f24716022662a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382239, encodeId=424a382239c4, content=这个思路不错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Apr 27 06:11:45 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1682605, encodeId=7d45168260521, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jul 10 16:14:27 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791614, encodeId=cd0f1e91614f5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 03 10:14:27 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382349, encodeId=3b9138234945, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Apr 30 06:11:44 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271084, encodeId=d1df12e1084c6, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364592, encodeId=29d91364592f8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602266, encodeId=f24716022662a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382239, encodeId=424a382239c4, content=这个思路不错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Apr 27 06:11:45 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1682605, encodeId=7d45168260521, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jul 10 16:14:27 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791614, encodeId=cd0f1e91614f5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 03 10:14:27 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382349, encodeId=3b9138234945, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Apr 30 06:11:44 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271084, encodeId=d1df12e1084c6, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364592, encodeId=29d91364592f8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602266, encodeId=f24716022662a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382239, encodeId=424a382239c4, content=这个思路不错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Apr 27 06:11:45 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
    2020-04-30 thm112988

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1682605, encodeId=7d45168260521, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jul 10 16:14:27 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791614, encodeId=cd0f1e91614f5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 03 10:14:27 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382349, encodeId=3b9138234945, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Apr 30 06:11:44 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271084, encodeId=d1df12e1084c6, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364592, encodeId=29d91364592f8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602266, encodeId=f24716022662a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382239, encodeId=424a382239c4, content=这个思路不错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Apr 27 06:11:45 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1682605, encodeId=7d45168260521, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jul 10 16:14:27 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791614, encodeId=cd0f1e91614f5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 03 10:14:27 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382349, encodeId=3b9138234945, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Apr 30 06:11:44 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271084, encodeId=d1df12e1084c6, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364592, encodeId=29d91364592f8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602266, encodeId=f24716022662a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382239, encodeId=424a382239c4, content=这个思路不错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Apr 27 06:11:45 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
    2020-04-28 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1682605, encodeId=7d45168260521, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jul 10 16:14:27 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791614, encodeId=cd0f1e91614f5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 03 10:14:27 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382349, encodeId=3b9138234945, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Apr 30 06:11:44 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271084, encodeId=d1df12e1084c6, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364592, encodeId=29d91364592f8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602266, encodeId=f24716022662a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382239, encodeId=424a382239c4, content=这个思路不错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Apr 27 06:11:45 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
    2020-04-28 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=1682605, encodeId=7d45168260521, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jul 10 16:14:27 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791614, encodeId=cd0f1e91614f5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 03 10:14:27 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382349, encodeId=3b9138234945, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Apr 30 06:11:44 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271084, encodeId=d1df12e1084c6, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364592, encodeId=29d91364592f8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602266, encodeId=f24716022662a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Apr 28 13:14:27 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382239, encodeId=424a382239c4, content=这个思路不错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Apr 27 06:11:45 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
    2020-04-27 njwbhuang

    这个思路不错。

    0

相关资讯

Ann Rheum Dis:靶向治疗可改善多关节型幼年特发性关节炎的疗效

T2T概念是可行的,并且优于无指导的治疗。12个月后,达到JADAS-MDA和JADA缓解的患者比例高。

Oncogene:PAK4可作为膀胱癌的治疗靶标

肌层浸润膀胱癌(MIBCs)是具有侵袭性的生殖泌尿系恶性肿瘤。膀胱的转移性尿路上皮癌在目前的化疗下无法治愈,并且能导致早期死亡。之前的研究鉴定了MIBCs的分子亚型,并且对前线疗法具有不同的敏感性,也

Brit J Cancer:一种新的预测前列腺癌患者结果的分层框架

无监督学习方法,比如层序聚类分析,经常用于基因组平台数据分析。但是,上述方法忽略了前列腺癌样本的异质性组成情况。最近,有研究人员使用了更加复杂的分析方法去解卷前列腺癌转录组数据结构,并为该疾病提供新的

Arthritis Rheumatol:两个早期类风湿性关节炎队列实施不同靶向治疗策略达到缓解的情况

两个队列中的大多数患者均达到了研究特定的治疗目标。随访期间,ARCTIC队列比NOR-VEAC队列达到ACR/EULAR布尔缓解的人数更多,这表明以更严格的缓解定义为治疗目标有助于为TTT策略提供有利的结局。

Nature:全新发现一种重要的癌症免疫治疗新方法:Gasdermin E

近期来自波士顿儿童医院发现了癌症免疫疗法的另外一种新武器,可以在更多的癌症类型中发挥作用。这种方法利用人体内免疫反应重新激活称为Gasdermin E的基因,这种基因在许多类型的癌症中均被抑制。

肝内胆管癌靶向治疗首次重大突破!Pemigatinib横空出世

复旦大学附属中山医院副院长周俭教授:“肝内胆管癌发病率约占原发性肝脏恶性肿瘤的15~20%,且呈上升趋势。大部分肝内胆管癌病人初次就诊时常伴有局部侵犯或远处转移而失去手术根治机会。以吉西他滨联合铂类的化疗方案被推荐为治疗晚期胆管癌的一线方案,客观反应率(ORR)为15~26%,且常发生耐药。目前,临床上缺乏其他有效的治疗药物和方案。” FGFR靶向药物的横空出世解决了胆管癌患者的燃眉之急,今